Unicycive Therapeutics, Inc. (UNCY) Stock Price & Growth Analysis - Tweevest

New

Chrome Plugin Live! Redefine the way you read FinTwit 🚀 Install Now

You have successfully sign out

Unicycive Therapeutics, Inc.

UNCY

NASDAQ

Unprofitable

Unprofitable

42M

Biotechnology

Next Earning date - 12 Nov 2024

42M

Biotechnology

Next Earning date - 12 Nov 2024

0.44USD

0.03 ( 6.57%)

Market Open

Relative Strenght

10

Volume Buzz

-42%

Earning Acce

No

Dist 52w H.

76%

Quote Panel

Updated October 28, 2024

1W 2.76 % 1M 8.58 % 3M 4.21 % 1Y -27.63 %

Key Metrics

Market Cap
41.72M
Shares Outstanding
94.36M
Share in Float
84.53M
Dividende
0

Earning Date
12 Nov 2024
Price Target
0.4422
Average Volume
2.23M
Beta
2.348

Range
0.202-1.818
Industry
Biotechnology
Website
https://www.unicycive.com
Sector
Healthcare

Fundamentals

N/A

P/E Ratio

Nanx

P/S Ratio

-1.06x

P/B Ratio

-3.1

Debt/Equity

10788.2%

Net Margin

$-0.4

EPS

How UNCY compares to sector?

P/E Ratio

Relative Strength

UNCY

Sector

loading...

Top 5 RS in Group

Symbol	Company	RS	5-Day Perf.

Forecast

$33M

NaN%

2025-Revenue

$0.34

-523%

2025-EPS

$7M

188%

2025-EBITDA

Analyst rating

No Data Available

Last analyst upgrade/downgrade

Piper Sandler

initialise

Previous: Not converted

2024-04-04

Now: Overweight

Earnings Growth

YoY

Current

Estimates

Q3.22

N/A

-0.37
vs -0.37

Q4.22

N/A

-0.35
vs -0.17

Q1.23

N/A

-0.29
vs -0.24

Q2.23

N/A

-0.29
vs -0.24

Q3.23

N/A

-0.13
vs -0.37

Q4.23

N/A

-0.16
vs -0.35

Q1.24

N/A

-0.27
vs -0.29

Q2.24

N/A

-0.15
vs -0.29

Q3.24

N/A

-0.15
vs -0.13

Q4.24

N/A

-0.14
vs -0.16

Sales Growth

YoY

Current

Estimates

Q2.22

NA

NA vs NA

Q3.22

NA

951K vs NA

Q4.22

NA

NA vs NA

Q1.23

NA

675K vs NA

Q2.23

NA

NA vs NA

Q3.23

-100%

NA vs 951K

Q4.23

NA

-271000.00 vs NA

Q1.24

-100%

NA vs 675K

Q2.24

NA

NA vs NA

Q4.24

+3790%

10M vs -271000

Return on Equity

QoQ

Q3.22

-120%

-1.20
vs -0.37

Q4.22

+1144%

11.44
vs -1.20

Q1.23

-239%

-2.39
vs 11.44

Q2.23

-56%

-0.56
vs -2.39

Q3.23

-128%

-1.28
vs -0.56

Q4.23

+205%

2.05
vs -1.28

Q1.24

+86%

0.86
vs 2.05

Q2.24

-26%

-0.26
vs 0.86

Institutionnal Ownership

QoQ

Q3.22

11

11
vs 14

-21%

Q4.22

9

9
vs 11

-18%

Q1.23

13

13
vs 9

44%

Q2.23

15

15
vs 13

15%

Q3.23

16

16
vs 15

7%

Q4.23

16

16
vs 16

NA

Q1.24

23

23
vs 16

44%

Q2.24

24

24
vs 23

4%

Earnings Growth

Latest News

UNCY

globenewswire.com

7 hours ago

Unicycive Therapeutics Delivers Multiple Poster Presentations Highlighting Development Progress on Oxylanthanum Carbonate (OLC) and UNI-494 at the American Society of Nephrology (ASN) Kidney Week 2024

UNCY

globenewswire.com

7 hours ago

Unicycive Therapeutics Announces Late-Breaker Poster Presentation on Oxylanthanum Carbonate (OLC) at the American Society of Nephrology (ASN) Kidney Week 2024

UNCY

globenewswire.com

7 hours ago

Unicycive Therapeutics Successfully Completes UNI-494 Phase 1 Study in Healthy Volunteers

UNCY

globenewswire.com

7 hours ago

Unicycive Therapeutics to Participate in a Fireside Chat at the Virtual Lytham Partners Fall 2024 Investor Conference on October 1, 2024

UNCY

globenewswire.com

7 hours ago

Unicycive Therapeutics to Present at the Virtual Life Sciences Investor Forum on September 19, 2024

UNCY

globenewswire.com

16 hours ago

Unicycive Therapeutics to Participate in a Fireside Chat at the 2024 Maxim Healthcare Virtual Summit on October 17, 2024

New Feature Coming Soon, Stay Tuned!

Shape

Shape